A growing number of employer group plans now include GLP-1s for obesity treatment, typically with BMI thresholds and prior authorization
In May 2025, CVS Caremark announced that anti-obesity (AOM) tirzepatide (sold as Zepbound) would be removed from its preferred formulary effective July 1, 2025, with AOM semaglutide (sold as Wegovy) designated as the preferred alternative
Some individuals choose to supplement their journey with products like GLP-1 Daily Support or a Weight Loss Boost supplement to ensure their body has the vitamins and minerals it needs while in a calorie deficit
Whether youre on a medication, considering one, or taking a food-first approach
HRP-labeled rabbit anti-rat IgG (ab6734) was purchased from Abcam (Cambridge, MA, USA)
Up to 30% of people with NAFLD develop NASH, a serious illness with inflammation and scarring